Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.

Mark A. Socinski, Frederic J. Kaye, David R. Spigel, Fred J. Kudrik, Santiago Ponce, Peter M. Ellis, Margarita Majem, Paul Lorigan, Leena Gandhi, Martin E. Gutierrez, Dale Nepert, Jesus Corral, Luis Paz-Ares

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science